In vivo fitness and virulence of a drug-resistant herpes simplex virus 1 mutant

References

1. Bacon T. H., Levin M. J., Leary J. J., Sarisky R. T., Sutton D. 2003; Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 16:114–128 [CrossRef]
   [Google Scholar]
2. Bean W. J., Threlkeld S. C., Webster R. G. 1989; Biologic potential of amantadine-resistant influenza A virus in an avian model. J Infect Dis 159:1050–1056 [CrossRef]
   [Google Scholar]
3. Chen S. H., Cook W. J., Grove K. L., Coen D. M. 1998; Human thymidine kinase can functionally replace herpes simplex virus type 1 thymidine kinase for viral replication in mouse sensory ganglia and reactivation from latency upon explant. J Virol 72:6710–6715
   [Google Scholar]
4. Coen D. M. 1994; Acyclovir-resistant, pathogenic herpesviruses. Trends Microbiol 2:481–485 [CrossRef]
   [Google Scholar]
5. Coen D. M., Richman D. D. 2007; Antiviral agents. In Fields Virology , 5th edn. pp 447–485 Edited by Knipe D. M., Howley P. M., Griffin D. E., Lamb R. A., Martin M. A., Roizman B., Straus S. E. Philadelphia, PA: Lippincott Williams & Wilkins;
   [Google Scholar]
6. Coen D. M., Schaffer P. A. 2003; Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat Rev Drug Discov 2:278–288 [CrossRef]
   [Google Scholar]
7. Coen D. M., Irmiere A. F., Jacobson J. G., Kerns K. M. 1989; Low levels of herpes simplex virus thymidine-thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model. Virology 168:221–231 [CrossRef]
   [Google Scholar]
8. Desai P., DeLuca N. A., Person S. 1998; Herpes simplex virus type 1 VP26 is not essential for replication in cell culture but influences production of infectious virus in the nervous system of infected mice. Virology 247:115–124 [CrossRef]
   [Google Scholar]
9. Enquist L. W., Husak P. J., Banfield B. W., Smith G. A. 1998; Infection and spread of alphaherpesviruses in the nervous system. Adv Virus Res 51:237–347
   [Google Scholar]
10. Field H. J., Coen D. M. 1986; Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene. J Virol 60:286–289
    [Google Scholar]
11. Jacobson J., Kramer M., Rozenberg F., Hu A., Coen D. M. 1995; Synergistic effects on ganglionic herpes simplex virus infections by mutations or drugs that inhibit the viral polymerase and thymidine kinase. Virology 206:263–268 [CrossRef]
    [Google Scholar]
12. Larder B. A., Darby G. 1984; Virus drug-resistance: mechanisms and consequences. Antiviral Res 4:1–42 [CrossRef]
    [Google Scholar]
13. Leib D. A., Coen D. M., Bogard C. L., Hicks K. A., Yager D. R., Knipe D. M., Tyler K. L., Schaffer P. A. 1989; Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J Virol 63:759–768
    [Google Scholar]
14. Newcomb W. W., Brown J. C. 2002; Inhibition of herpes simplex virus replication by WAY-150138: assembly of capsids depleted of the portal and terminase proteins involved in DNA encapsidation. J Virol 76:10084–10088 [CrossRef]
    [Google Scholar]
15. Newcomb W. W., Juhas R. M., Thomsen D. R., Homa F. L., Burch A. D., Weller S. K., Brown J. C. 2001; The UL6 gene product forms the portal for entry of DNA into the herpes simplex virus capsid. J Virol 75:10923–10932 [CrossRef]
    [Google Scholar]
16. Newcomb W. W., Thomsen D. R., Homa F. L., Brown J. C. 2003; Assembly of the herpes simplex virus capsid: identification of soluble scaffold-portal complexes and their role in formation of portal-containing capsids. J Virol 77:9862–9871 [CrossRef]
    [Google Scholar]
17. Oxford J. S., Potter C. W. 1973; Aminoadamantane-resistant strains of influenza A2 virus. J Hyg (Lond) 71:227–236 [CrossRef]
    [Google Scholar]
18. Patel A. H., Rixon F. J., Cunningham C., Davison A. J. 1996; Isolation and characterization of herpes simplex virus type 1 mutants defective in the UL6 gene. Virology 217:111–123 [CrossRef]
    [Google Scholar]
19. Pelosi E., Mulamba G. B., Coen D. M. 1998a; Penciclovir and pathogenesis phenotypes of drug-resistant herpes simplex virus mutants. Antiviral Res 37:17–28 [CrossRef]
    [Google Scholar]
20. Pelosi E., Rozenberg F., Coen D. M., Tyler K. L. 1998b; A herpes simplex virus DNA polymerase mutation that specifically attenuates neurovirulence in mice. Virology 252:364–372 [CrossRef]
    [Google Scholar]
21. Pesola J. M., Zhu J., Knipe D. M., Coen D. M. 2005; Herpes simplex virus 1 immediate-early and early gene expression during reactivation from latency under conditions that prevent infectious virus production. J Virol 79:14516–14525 [CrossRef]
    [Google Scholar]
22. Safrin S., Elbeik T., Phan L., Robinson D., Rush J., Elbaggari A., Mills J. 1994; Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 38:1246–1250 [CrossRef]
    [Google Scholar]
23. Sherman G., Bachenheimer S. L. 1988; Characterization of intranuclear capsids made by ts morphogenic mutants of HSV-1. Virology 163:471–480 [CrossRef]
    [Google Scholar]
24. Stevens J. G., Cook M. L. 1971; Latent herpes simplex virus in spinal ganglia of mice. Science 173:843–845 [CrossRef]
    [Google Scholar]
25. Sweet C., Hayden F. G., Jakeman K. J., Grambas S., Hay A. J. 1991; Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis 164:969–972 [CrossRef]
    [Google Scholar]
26. Tenser R. B., Dunstan M. E. 1979; Herpes simplex virus thymidine kinase expression in infection of the trigeminal ganglion. Virology 99:417–422 [CrossRef]
    [Google Scholar]
27. Tran R. K., Lieu P. T., Aguilar S., Wagner E. K., Bloom D. C. 2002; Altering the expression kinetics of VP5 results in altered virulence and pathogenesis of herpes simplex virus type 1 in mice. J Virol 76:2199–2205 [CrossRef]
    [Google Scholar]
28. Trus B. L., Cheng N., Newcomb W. W., Homa F. L., Brown J. C., Steven A. C. 2004; Structure and polymorphism of the UL6 portal protein of herpes simplex virus type 1. J Virol 78:12668–12671 [CrossRef]
    [Google Scholar]
29. van Zeijl M., Fairhurst J., Jones T. R., Vernon S. K., Morin J., LaRocque J., Feld B., O'Hara B., Bloom J. D., Johann S. V. 2000; Novel class of thiourea compounds that inhibit herpes simplex virus type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene. J Virol 74:9054–9061 [CrossRef]
    [Google Scholar]
30. Visalli R. J., van Zeijl M. 2003; DNA encapsidation as a target for anti-herpesvirus drug therapy. Antiviral Res 59:73–87 [CrossRef]
    [Google Scholar]
31. Zhao Z. S., Granucci F., Yeh L., Schaffer P. A., Cantor H. 1998; Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science 279:1344–1347 [CrossRef]
    [Google Scholar]